Brokerages Anticipate PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) to Announce -$0.67 Earnings Per Share

Wall Street analysts forecast that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHASGet Rating) will post ($0.67) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for PhaseBio Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.63) and the lowest estimate coming in at ($0.76). PhaseBio Pharmaceuticals reported earnings of ($0.87) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 23%. The business is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that PhaseBio Pharmaceuticals will report full-year earnings of ($2.22) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($1.72). For the next financial year, analysts anticipate that the firm will report earnings of ($1.66) per share, with EPS estimates ranging from ($2.09) to ($1.16). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals (NASDAQ:PHASGet Rating) last released its quarterly earnings results on Thursday, March 24th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.51). The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $4.92 million.

Separately, Needham & Company LLC dropped their target price on PhaseBio Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 28th.

PhaseBio Pharmaceuticals stock traded up $0.12 during trading hours on Tuesday, reaching $1.09. The stock had a trading volume of 2,612 shares, compared to its average volume of 570,204. PhaseBio Pharmaceuticals has a 52 week low of $0.96 and a 52 week high of $4.24. The business’s 50 day moving average price is $1.21 and its 200-day moving average price is $1.96. The company has a market cap of $53.07 million, a price-to-earnings ratio of -0.35 and a beta of 1.98.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James & Associates purchased a new stake in shares of PhaseBio Pharmaceuticals in the fourth quarter valued at approximately $40,000. IPG Investment Advisors LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the 4th quarter worth approximately $76,000. Squarepoint Ops LLC raised its position in shares of PhaseBio Pharmaceuticals by 29.8% during the 3rd quarter. Squarepoint Ops LLC now owns 27,083 shares of the company’s stock valued at $84,000 after buying an additional 6,216 shares during the period. Pura Vida Investments LLC purchased a new stake in shares of PhaseBio Pharmaceuticals during the 3rd quarter valued at approximately $87,000. Finally, Citadel Advisors LLC lifted its holdings in PhaseBio Pharmaceuticals by 169.3% in the fourth quarter. Citadel Advisors LLC now owns 37,452 shares of the company’s stock valued at $98,000 after acquiring an additional 23,545 shares during the last quarter. Hedge funds and other institutional investors own 57.43% of the company’s stock.

PhaseBio Pharmaceuticals Company Profile (Get Rating)

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure.

Recommended Stories

Get a free copy of the Zacks research report on PhaseBio Pharmaceuticals (PHAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PhaseBio Pharmaceuticals (NASDAQ:PHAS)

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.